| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/15/2009 | US20090017501 Interferon-alpha polypeptides and conjugates |
| 01/15/2009 | US20090017500 Covalently attached to a nonpeptide moiety; nucleic acids encoding the polypeptides; reducing the number of copies of a virus in infected cells; administering antiviral polypeptide |
| 01/15/2009 | US20090017479 Ly6h gene |
| 01/15/2009 | US20090017478 High-throughput enzyme-linked immuno absorbent assay (elisa) for determination of rho-kinase (rok) activity |
| 01/15/2009 | US20090017471 SOLUBLE ErbB3 METHOD OF DETECTION |
| 01/15/2009 | US20090017467 COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV |
| 01/15/2009 | US20090017137 Methods and compositions for the prevention and treatment of anemia |
| 01/15/2009 | US20090017123 Dermal regeneration enhancer |
| 01/15/2009 | US20090017108 Liposome compositions for treatment of hepatitis C |
| 01/15/2009 | US20090017103 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 01/15/2009 | US20090017100 Pharmaceutical composition, food or drink, or feed for intestinal disease |
| 01/15/2009 | US20090017097 Hydrogel polymeric compositions and methods |
| 01/15/2009 | US20090017077 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/15/2009 | US20090017076 Treatment for cd5+ b cell lymphoma |
| 01/15/2009 | US20090017073 Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
| 01/15/2009 | US20090017071 Methods for treating neurogenic inflammation |
| 01/15/2009 | US20090017049 BetaGBP, compositions comprising betaGBP, and related methods and uses thereof |
| 01/15/2009 | US20090017045 relate to various cell proliferative disorders, especially those involving muscle, nerve, and adipose tissue |
| 01/15/2009 | US20090017034 inhibits thymic stromal lymphopoietin TSLP)-mediated lymphocyte stimulation; using these polypeptides as molecular weight markers that allow the estimation of the molecular weight of a protein or a fragmented protein |
| 01/15/2009 | US20090017033 Inhibiting receptor activated nuclear factor kappa beta ligand (RANKL); immunoregulation |
| 01/15/2009 | US20090017032 Mammalian cx3c chemokine antibodies |
| 01/15/2009 | US20090017031 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 01/15/2009 | US20090017030 Endothelial Cell Expression Patterns |
| 01/15/2009 | US20090017029 Methods and Compositions for Treating Ocular Disorders |
| 01/15/2009 | US20090017024 Methods and Compositions for the Treatment of Cancer, Tumors, and Tumor-Related Disorders |
| 01/15/2009 | US20090017022 Sulfatases and methods of use thereof |
| 01/15/2009 | US20090017019 Methods and compositions for modulating bmp-10 activity |
| 01/15/2009 | US20090017018 Uses of mammalian cytokine: related reagents |
| 01/15/2009 | US20090017015 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | US20090017013 cyclosporine; autoimmunity to type V collagen ; for Idiopathic Pulmonary Fibrosis, Adult Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome, secondary collagen vascular disease, any form of fibrotic lung disease |
| 01/15/2009 | US20090017011 Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis |
| 01/15/2009 | US20090017009 Method for the diagnosis and prognosis of malignant diseases |
| 01/15/2009 | US20090017007 Liquid factor vii composition |
| 01/15/2009 | US20090017006 Use of a compound for enhancing the expression of membrane proteins on the cell surface |
| 01/15/2009 | US20090017005 Delivery of Therapeutic Compounds to the Brain and Other Tissues |
| 01/15/2009 | US20090017004 Polymeric drug delivery systems containing an aromatic allylic acid |
| 01/15/2009 | US20090017003 Thiosulfonate anti-inflammatory agents |
| 01/15/2009 | US20090017002 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 01/15/2009 | US20090017001 Ambient stored blood plasma expanders |
| 01/15/2009 | US20090016992 Pcv2 immunogenic compositions and methods of producing such compositions |
| 01/15/2009 | US20090016991 Rxr Antagonist Treatment Against Multiple Sclerosis |
| 01/15/2009 | US20090016989 Antibodies to human somatostatin receptor and methods of use |
| 01/15/2009 | US20090016988 Modified Pore-Forming Protein Toxins and Use Thereof |
| 01/15/2009 | US20090016987 Pharmaceutical composition and therapeutic method |
| 01/15/2009 | US20090016970 Continuous spray scalp therapy and dispensing systems for same |
| 01/15/2009 | US20090016959 Drug delivery across the blood-brain barrier using polypeptides; neurological diseases; aprotinin |
| 01/15/2009 | US20090016957 Polypeptides |
| 01/15/2009 | US20090014562 Spray Nozzle Apparatus and Method of Use |
| 01/15/2009 | US20090013998 Inhalable tiotropium and container therefor |
| 01/15/2009 | DE4407386B4 Verfahren zur Reaktivierung von gereinigten Membranproteinen durch Einfrieren A process for reactivating purified membrane proteins by freezing |
| 01/15/2009 | DE10222714B4 Kofaktoren, die spezifisch mit dem Glukokortikoidrezeptor interagieren sowie Verfahren zu deren Identifizierung Cofactors, specifically interact with the glucocorticoid receptor and methods for their identification |
| 01/15/2009 | DE102007033067A1 Zubereitungen zur Verbesserung des Schutzes menschlicher Zellen, insbesondere Zellen der menschlichen Haut vor schädigenden Einflüssen durch oxidative Noxen und UV-Bestrahlung Preparations to improve the protection of human cells, especially cells of human skin against harmful influences by oxidative toxicants and UV irradiation |
| 01/15/2009 | CA2728568A1 Composition and packaging method for animal dental care |
| 01/15/2009 | CA2693785A1 Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
| 01/15/2009 | CA2693717A1 Immunology treatment for biofilms |
| 01/15/2009 | CA2693651A1 Bioactive peptides and method of using same |
| 01/15/2009 | CA2693646A1 Normal-tension glaucoma model and method for evaluation of test substances by using same |
| 01/15/2009 | CA2693392A1 Novel compounds and their effects on feeding behaviour |
| 01/15/2009 | CA2692802A1 Tnf superfamily collectin fusion proteins |
| 01/15/2009 | CA2692800A1 Detection of micro-organisms based on their nad-dependent dna ligase activity |
| 01/15/2009 | CA2692791A1 Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages |
| 01/15/2009 | CA2692682A1 Methods and compositions useful in the treatment of mucositis |
| 01/15/2009 | CA2692637A1 Treatment and diagnostic methods for fibrosis related disorders |
| 01/15/2009 | CA2691898A1 Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury |
| 01/15/2009 | CA2691695A1 Glp-1-fc fusion protein formulation |
| 01/15/2009 | CA2691604A1 Use of a chromatography substrate for reducing the amount of adamts13 in a solution derived from plasma |
| 01/15/2009 | CA2691068A1 Use of a haemoglobin for the preparation of dressings and resulting dressings |
| 01/15/2009 | CA2690773A1 Pharmaceutical liquid composition of botulinum toxin with improved stability |
| 01/15/2009 | CA2683712A1 Pharmaceutical compositions |
| 01/15/2009 | CA2682096A1 Klotho beta |
| 01/14/2009 | EP2014770A2 WNT-1 Iinduced secreted polypeptide WISP-2 |
| 01/14/2009 | EP2014679A1 KDR peptides and vaccines comprising the same |
| 01/14/2009 | EP2014678A2 KDR peptides and vaccines comprising the same |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014675A1 Compositions and methods for the treatment of immune related diseases |
| 01/14/2009 | EP2014674A1 Protein-protein interactions in human immunodeficiency virus |
| 01/14/2009 | EP2014673A1 Tumour-associated peptides which bind to MHC molecules |
| 01/14/2009 | EP2014310A2 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| 01/14/2009 | EP2014303A2 APO-2L receptor agonist and CPT-11 synergism |
| 01/14/2009 | EP2014299A1 Subcutaneous administration of coagulation factor VII |
| 01/14/2009 | EP2014298A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014296A1 Novel strategies for increasing the reperfusion in obstructed blood vessel |
| 01/14/2009 | EP2014284A1 Pharmaceutical compositions and uses |
| 01/14/2009 | EP2014279A1 Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| 01/14/2009 | EP2013235A1 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 01/14/2009 | EP2013233A2 Use of tm-601 for the diagnosis and treatment of tumors |
| 01/14/2009 | EP2013228A1 Methods of inducing apoptosis of cancerous cells using apoptin derivatives |
| 01/14/2009 | EP2013226A2 Processes for the preparation of octreotide |
| 01/14/2009 | EP2013200A2 Polyamides for treating human papilloma virus |
| 01/14/2009 | EP2012842A2 Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions |
| 01/14/2009 | EP2012826A2 Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases |
| 01/14/2009 | EP2012819A2 Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
| 01/14/2009 | EP2012818A1 Hydrolysate of avian cartilage, process of preparation and uses thereof |
| 01/14/2009 | EP2012817A2 Rapid acting and long acting insulin combination formulations |
| 01/14/2009 | EP2012816A1 Use of thymosin 1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection |
| 01/14/2009 | EP2012815A2 Identifying and modulating molecular pathways that mediate nervous system plasticity |
| 01/14/2009 | EP2012814A1 Methods of treating autoimmune diseases |
| 01/14/2009 | EP2012812A2 Medicaments and proteins based on tgf-beta monomers for the treatment of wounds |